Nasdaq Srpt News Today

Cantor Fitzgerald reiterated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report report published on Thursday morning, Benzinga reports. They currently have a $128.00 target price on the biotechnology company’s stock. Other equities analysts also recently issued research reports about the company. Wedbush reissued an outperform rating and […]

Needham & Company LLC restated their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report published on Thursday morning, Benzinga reports. Needham & Company LLC currently has a $166.00 target price on the biotechnology company’s stock. SRPT has been the topic of several other research reports. TheStreet raised Sarepta Therapeutics […]

Sapient Capital LLC purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,146 shares of the biotechnology company’s stock, valued at approximately $978,000. Several other institutional investors also recently bought […]

Mach 1 Financial Group LLC acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 5,144 shares of the biotechnology company’s stock, valued at approximately $496,000. Several other hedge funds have also […]

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s share price gapped up before the market opened on Thursday following a stronger than expected earnings report. The stock had previously closed at $130.90, but opened at $140.00. Sarepta Therapeutics shares last traded at $136.00, with a volume of 574,101 shares changing hands. The biotechnology company reported […]

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a research report issued on Thursday, Benzinga reports. They presently have a $166.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 26.81% […]

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fourteen brokerages that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average […]

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Stock analysts at William Blair reduced their FY2024 EPS estimates for Sarepta Therapeutics in a research report issued on Wednesday, April 17th. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings per share of $6.66 for the year, down from their previous […]

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month price objective among […]

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has earned an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month target price […]